Rapivab is an intravenous treatment for severe flu, approved this month for children aged 2-18. It has been used for adults for almost three years.
Rapivab is an intravenous treatment for severe flu, approved this month for children aged 2-18. It has been used for adults for almost three years. Andrea Reese Photography BioCryst Pharmaceuticals
Rapivab is an intravenous treatment for severe flu, approved this month for children aged 2-18. It has been used for adults for almost three years. Andrea Reese Photography BioCryst Pharmaceuticals